<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054413</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1096</org_study_id>
    <secondary_id>NCI-2021-01928</secondary_id>
    <secondary_id>2020-1096</secondary_id>
    <nct_id>NCT05054413</nct_id>
  </id_info>
  <brief_title>Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method</brief_title>
  <official_title>Key Elements for Standardized Reporting in Prostate Cancer Management: An Expert Delphi Consensus Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study formulates consensus agreement on clinical key elements related to prostate cancer&#xD;
      care that are critical for standardization and global reported using a robust Delphi&#xD;
      technique, completely remote and electronic. The goal of this survey study is to have a panel&#xD;
      of specialty-specific experts create a consensus agreement on a minimum set of key data&#xD;
      elements for use in standardized reports. These recommendations would be used to develop&#xD;
      standardized methods to report key data in electronic health records to better manage cancer&#xD;
      patients at time of diagnosis, treatment, follow up, and into survivorship.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To formulate consensus agreement on a minimum set of clinical key elements that should be&#xD;
      included in standardized reports in electronic health records when managing patients with&#xD;
      prostate cancer.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To establish a standardized methods to report key data in electronic health records to better manage cancer patients at time of diagnosis, treatment, follow up, and into survivor-ship.</measure>
    <time_frame>through study completion, an average of a year.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (questionnaire)</arm_group_label>
    <description>Participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (questionnaire)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with board certification in Radiation Oncology, Radiation Physics, Urology,&#xD;
        and/or Medical Oncology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 and above&#xD;
&#xD;
          -  Board certification in Radiation Oncology, Radiation Physics, Urology, and/or Medical&#xD;
             Oncology&#xD;
&#xD;
          -  Maintenance of an active practice that includes prostate cancer patients&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical providers that are not board certified in the professions and/or those who do&#xD;
             not treat prostate cancer&#xD;
&#xD;
          -  Prisoners, children, and adults unable to consent to participation will also be&#xD;
             excluded&#xD;
&#xD;
          -  No exclusions were made based on sex, age, racial/ethnic background, or pregnancy&#xD;
             status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy C Moreno</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy C. Moreno</last_name>
      <phone>832-728-6162</phone>
      <email>akmoreno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Amy C. Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

